Tirzepatide Guides
Released: Last reviewed: Updated:
In-depth guides on cost, dosing, side effects, insurance coverage, and pharmacy pathways for tirzepatide.
Tirzepatide patient guides
Patient-focused guides covering the practical questions most people ask before, during, and after starting tirzepatide therapy. Each guide is built around how this question affects real treatment decisions: cost, insurance, dosing, side effects, and what compounded versus brand-name means. For deeper clinical reference, see the clinical reference section; for state-specific access information, see tirzepatide by state; for direct head-to-head comparisons, see side-by-side comparisons.
All pages in this section
- Cost guide — Brand-name prices, insurance pathways, manufacturer self-pay programs (Lilly's vial program for Zepbound), compounded pricing, and total annual cost projection.
- Insurance coverage — Commercial coverage, Medicare for diabetes vs weight loss, Medicaid variability by state, prior authorization criteria, and how to navigate denials.
- Dosing guide — The standard 2.5 mg → 15 mg titration, what to expect at each step, slower-titration tactics for GI intolerance, and missed-dose handling.
- Managing side effects — Common GI side effects, mitigation strategies, when to slow titration, when to call a clinician, and red-flag symptoms requiring urgent evaluation.
- How it works — Dual GIP/GLP-1 receptor agonism explained for patients — including why this dual mechanism produces more weight loss than GLP-1-only medications.
- BMI & eligibility — FDA-labeled BMI criteria (≥30, or ≥27 with weight-related comorbidity), how providers verify BMI in telehealth, and what counts as a qualifying comorbidity.
- 503A vs 503B pharmacies — What 503A traditional compounding and 503B outsourcing facilities are, how they differ in oversight, and what to look for when verifying a compounding pharmacy.
- Compounded vs brand — The clinical, regulatory, and cost differences between compounded tirzepatide and FDA-approved Mounjaro or Zepbound — and how to make an informed choice.
Frequently asked questions
How do I get started on tirzepatide?
Most patients begin with a telehealth or in-person clinical visit to verify eligibility (BMI ≥30 or ≥27 with comorbidity for weight management; diabetes diagnosis for type 2 diabetes care). The provider reviews medical history, contraindications, and current medications, then writes a prescription. Insurance coverage is verified or a cash-pay pathway is chosen, and the medication is dispensed by a pharmacy.
How much does tirzepatide cost without insurance?
Brand-name Zepbound list price is approximately $1,060 per month in 2026; Eli Lilly's self-pay vial program for select doses costs $349–$549 per month. Compounded tirzepatide from licensed pharmacies typically prices between $159 and $399 per month depending on dose and provider. Total annual cost without insurance can range from approximately $1,800 to $12,000+.
How long until I see results on tirzepatide?
Weight loss typically begins within the first few weeks but is most pronounced over months. Mean weight loss continued through 72 weeks of treatment in the SURMOUNT-1 trial. Many patients see 5–10% body weight loss by month 3 and 15–20% by month 12 on adequate dosing.
Can I stop tirzepatide once I reach my goal weight?
Most clinicians recommend continuing tirzepatide as long-term therapy. The SURMOUNT-4 trial demonstrated substantial weight regain when patients were switched to placebo after initial weight loss. Tirzepatide is positioned analogously to medications for other chronic conditions — taken indefinitely under clinical supervision.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022